AstraZeneca
Public Health

FDA temporarily halts deployment of AstraZeneca vaccines

Apr 9, 2021, 3:51 AM
OpinYon News Team

OpinYon News Team

News Reporter

The Food and Drug Administration has cited the occurrence of rare blood clotting in its recommendation to temporarily halt the use of the AstraZeneca vaccine.

Several countries in Europe have also temporarily stopped the deployment of the AstraZeneca vaccine after concerns that it can cause rare blood clots

IN a move that could surely send chills to the spine of many of who already received their shots, the Food and Drug Administration (FDA) has recommended a temporary halt in the deployment of AstraZeneca Covid-19 vaccines in the country.

In a report, the FDA said it specifically recommended to stop the use of the AstraZeneca vaccine to persons 60 years old and below.

The agency cited growing concerns about blood clotting among recipients of the vaccine as the cause for its recommendation.

Several countries in Europe have also temporarily stopped the deployment of the AstraZeneca vaccine after concerns that it can cause rare blood clots.

The European Medicines Agency (EMA) said a particular combination of unusual blood clots with low blood platelet counts should be listed as a side effect of the vaccine.

However, the benefits of the shot outweigh the risks and Covid-19 is a "very serious disease," it added.

Authorities in Italy and Great Britain have recommended that the use of the AstraZeneca vaccine be limited to persons over 60 years old. (ONT)

Tags: #Covid19, #Covid19vaccine, #AstraZeneca, #FoodandDrugAdministration


We take a stand
OpinYon News logo

Designed and developed by Simmer Studios.

© 2024 OpinYon News. All rights reserved.